These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33389539)

  • 1. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
    Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
    Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism.
    Luo M; Peng D
    Lipids Health Dis; 2016 Oct; 15(1):184. PubMed ID: 27770802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
    Taskinen MR; Packard CJ; Borén J
    Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting APOC3 in the familial chylomicronemia syndrome.
    Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
    N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein C-II: the re-emergence of a forgotten factor.
    Wolska A; Reimund M; Remaley AT
    Curr Opin Lipidol; 2020 Jun; 31(3):147-153. PubMed ID: 32332429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the S2 allele of the SstI polymorphism in the apoC3 gene with plasma apoCIII interacts with unfavorable lipid profiles to contribute to atherosclerosis in the Li ethnic group in China.
    Sun M; Chen L; Liu H; Ma L; Wang T; Liu Y
    Lipids Health Dis; 2017 Nov; 16(1):220. PubMed ID: 29162127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
    Kohan AB
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
    Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
    Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.
    Martinelli N; Trabetti E; Bassi A; Girelli D; Friso S; Pizzolo F; Sandri M; Malerba G; Pignatti PF; Corrocher R; Olivieri O
    Atherosclerosis; 2007 Apr; 191(2):409-17. PubMed ID: 16682041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olezarsen, a liver-directed
    Hooper AJ; Bell DA; Burnett JR
    Expert Opin Pharmacother; 2024 Oct; 25(14):1861-1866. PubMed ID: 39305266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
    Packard CJ; Pirillo A; Tsimikas S; Ference BA; Catapano AL
    Cardiovasc Res; 2024 Feb; 119(18):2843-2857. PubMed ID: 38039351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.
    Valdivielso P; Coca Prieto I
    Med; 2024 Jun; 5(6):493-494. PubMed ID: 38878767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis.
    Wyler von Ballmoos MC; Haring B; Sacks FM
    J Clin Lipidol; 2015; 9(4):498-510. PubMed ID: 26228667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Dancer M; Caussy C; Di Filippo M; Moulin P; Marçais C; Charrière S
    Atherosclerosis; 2016 Dec; 255():6-10. PubMed ID: 27794214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Chan DC; Watts GF
    Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
    Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
    Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.